未登录

V

Vaishali Sahasrabudhe

Pfizer Inc

H指数:17

被引数:698

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quantitative Sciences in the Model-Informed Era: From Parallel Functions to a Shared Decision System

模型指导时代的定量科学：从并行功能到共享决策系统

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2026-10-280

PRE

Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray

基于生理的药代动力学建模，用于评估转运体介导的药物-药物相互作用，以支持Zavegepant鼻喷雾剂的标签建议

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2026-09-050

OAAI

Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

模型指导药物研发对药物研发周期及临床试验成本的影响

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-03-260

OAAI

Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development-An IQ Perspective

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-02-230

PRE

An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-10-220

OAAI

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

IF3.7

2024-06-062

OA

Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-03-062

OAAI

Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-12-1811

OAAI

Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-06-172

OAAI

End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitor

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-05-159

OAAI

Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-03-163

PREAI

Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-12-3014

OAAI

Comparative Efficacy of Ertugliflozin (ERTU) plus Sitagliptin (SITA) vs. Other Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) + Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Combinations: Model-Based Meta-analysis (MBMA) of HbA1c Lowering

IF7.5

2019-06-010

PRE

Comparative Efficacy of Ertugliflozin (ERTU) vs. Other Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Model-Based Meta-analysis (MBMA) of HbA1c Lowering

IF7.5

2019-06-013

PRE

Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment

肝功能不全患者单剂量Ertugliflozin的药代动力学

CLINICAL THERAPEUTICS

IF3.6

2018-10-0118

PREAI

Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects

CLINICAL THERAPEUTICS

IF3.6

2018-09-0115

PREAI

Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2018-03-2533

OAAI

Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2015-05-2518

OAAI

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2011-10-2146

OAAI

Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2009-03-0119

PRE